Global Materials Network Extensive donor network and global collection centers enable reliable supply of fresh and cryopreserved human-derived cellular material from peripheral blood, bone marrow, and cord blood. This creates a compelling selling point for biotech and pharma clients in drug discovery and cell therapy process development who need a dependable, customizable starting material supplier and can benefit from end-to-end support.

Expanded Portfolio Advantage Expanded product portfolio with GMPrime cryopreserved leukopak and GMP-compliant bone marrow aspirate broadens material options for cell therapy and related research. This makes HemaCare an attractive one-stop source for GMP starting materials, potentially enabling bundled offerings with Charles River's discovery and manufacturing services.

CRL Integration Opportunity Positioned as a Charles River company, HemaCare can be offered alongside CRL's early discovery, safety assessment, and manufacturing portfolio to create bundled solutions. This presents sales opportunities to current CRL customers and to teams seeking integrated material supply with development services.

Cell Therapy Demand Rising demand for cell and gene therapies drives need for high quality human-derived materials. HemaCare supports this trend with fresh and cryopreserved PBMCs, leukopaks, and bone marrow derivatives, including GMP compliant options, helping clients shorten development timelines.

Strategic Partnerships Strategic partnerships such as the Tissue Solutions collaboration expand disease-state biomaterials offerings and could be extended with additional suppliers. This creates opportunities to target biotech clients needing disease-specific materials and to coordinate co-marketing with partner organizations to broaden reach.